Novartis could pay up to $3.223 billion (€2.8 billion) for access to Alteogen's technology for turning intravenous biologics ...
French biotech Transgene said all 16 head and neck cancer patients treated with its personalized cancer vaccine TG4050 in a ...
Italian pharma Menarini Group has licensed European rights to bofanglutide for obesity and excess weight, a long-acting GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results